Advertisement

Provoked seizures might lead to a significant diagnosis delay in CLN2

Published:August 28, 2022DOI:https://doi.org/10.1016/j.ejpn.2022.08.008
      When facing (new) clinical challenges, the ancient Greek view of the world should not be lost out of our sight. The assertion might seem surprising, but it touches the very foundation of our insights, findings, discoveries: it were Greeks who managed to notice differences and discontinuities where others perceived only sameness and continuity. And it could be argued that, eventually, this is the message of the paper by Kravljanac and Vučetić Tadić [
      • Kravljanac R.
      • Vučetić Tadić B.
      Provoked seizures at the onset of progressive disease contribute to diagnosis delay - a tertiary center experience in a cohort of 22 children with CLN2.
      ].
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Paediatric Neurology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Kravljanac R.
        • Vučetić Tadić B.
        Provoked seizures at the onset of progressive disease contribute to diagnosis delay - a tertiary center experience in a cohort of 22 children with CLN2.
        Eur. J. Paediatr. Neurol. 2022; 40: 1-4https://doi.org/10.1016/j.ejpn.2022.06.014
        • Williams R.E.
        • Adams H.R.
        • Blohm M.
        • et al.
        Management strategies for CLN2 disease.
        Pediatr. Neurol. 2017; 69: 102-112https://doi.org/10.1016/j.pediatrneurol.2017.01.034
        • Estublier B.
        • Cano A.
        • Hoebeke C.
        • et al.
        Cerliponase alfa changes the natural history of children with neuronal ceroid lipofuscinosis type 2: The first French cohort.
        Eur. J. Paediatr. Neurol. 2021; 30: 17-21https://doi.org/10.1016/j.ejpn.2020.12.002
        • Nickel M.
        • Simonati A.
        • Jacoby D.
        • et al.
        Disease characteristics and progression in patients with late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease: an observational cohort study.
        Lancet Child Adolesc Health. 2018; 2: 582-590
        • Mole S.E.
        • Anderson G.
        • Band H.A.
        • et al.
        Clinical challenges and future therapeutic approaches for neuronal ceroid lipofuscinosis.
        Lancet Neurol. 2018; 18: 107-116https://doi.org/10.1016/S1474-4422(18)30368-5